ARTELO BIOSCIENCES, INC. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
ARTELO BIOSCIENCES, INC. (ARTL) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $571.00 thousand for the 3-month period ending 2021-11-30, per its 10-Q filed 2022-01-12.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2022-03-21
- ARTELO BIOSCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2021-11-30 was $571.00K, a 1292.68% increase year-over-year.
- ARTELO BIOSCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2021-05-31 was $609.69K, a 1335.17% increase year-over-year.
- ARTELO BIOSCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2021-02-28 was $330.95K, a 239.79% increase year-over-year.
- ARTELO BIOSCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2020-11-30 was $41.00K, a 73.55% decline year-over-year.
- ARTELO BIOSCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2021 was $1.50M, a 345.54% increase from fiscal 2020.
- ARTELO BIOSCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2020 was $336.00K.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 3 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 3 month as first filed | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 6 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 9 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month as first filed |
|---|---|---|---|---|---|---|
| 2021-11-30 | $571.00K 10-Q · filed 2022-01-12 | |||||
| 2021-08-31 | $1.50M 10-KT · filed 2022-03-21 | |||||
| 2021-05-31 | $609.69K 10-Q · filed 2021-07-12 | $940.64K derived: sum of 2 quarters · filed 2021-07-12 | $981.64K derived: sum of 3 quarters · filed 2022-01-12 | |||
| 2021-02-28 | $330.95K 10-Q · filed 2021-07-12 | $371.95K derived: sum of 2 quarters · filed 2022-01-12 | ||||
| 2020-11-30 | $41.00K 10-Q · filed 2022-01-12 | $40.87K 10-Q · filed 2021-01-14 | ||||
| 2020-08-31 | $336.00K 10-KT · filed 2022-03-21 | $335.77K 10-K · filed 2020-11-04 | ||||
| 2020-05-31 | $42.48K 10-Q · filed 2021-07-12 | $139.88K derived: sum of 2 quarters · filed 2021-07-12 | $294.90K derived: sum of 3 quarters · filed 2021-07-12 | |||
| 2020-02-29 | $97.40K 10-Q · filed 2021-07-12 | $252.42K derived: sum of 2 quarters · filed 2021-07-12 | ||||
| 2019-11-30 | $155.02K 10-Q · filed 2021-07-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |